These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 38862756)

  • 1. Comparative study of MAFLD as a predictor of metabolic disease treatment for NAFLD.
    Imai J; Takashimizu S; Suzuki N; Ohshinden K; Sawamoto K; Mishima Y; Tsuruya K; Arase Y; Yamano M; Kishimoto N; Yamada C; Inoue N; Moriyama K; Baba A; Suzuki H; Kagawa T; Nishizaki Y
    Sci Rep; 2024 Jun; 14(1):13411. PubMed ID: 38862756
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic Fatty Liver Disease Without Metabolic-associated Fatty Liver Disease and the Risk of Metabolic Syndrome.
    Sinn DH; Kang D; Choi SC; Hong YS; Zhao D; Guallar E; Park Y; Cho J; Gwak GY
    Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1873-1880.e1. PubMed ID: 36152895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
    Staufer K; Huber-Schönauer U; Strebinger G; Pimingstorfer P; Suesse S; Scherzer TM; Paulweber B; Ferenci P; Stimpfl T; Yegles M; Datz C; Trauner M
    J Hepatol; 2022 Oct; 77(4):918-930. PubMed ID: 35605744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of all-cause mortality associated with non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease in Taiwan MJ cohort.
    Cheng WC; Chen HF; Cheng HC; Li CY
    Epidemiol Health; 2024; 46():e2024024. PubMed ID: 38317531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of MAFLD and NAFLD diagnostic criteria in real world.
    Lin S; Huang J; Wang M; Kumar R; Liu Y; Liu S; Wu Y; Wang X; Zhu Y
    Liver Int; 2020 Sep; 40(9):2082-2089. PubMed ID: 32478487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study.
    Wang X; Wu S; Yuan X; Chen S; Fu Q; Sun Y; Lan Y; Hu S; Wang Y; Lu Y; Qu S; Wang L
    J Clin Endocrinol Metab; 2022 Jan; 107(2):e745-e755. PubMed ID: 34467980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic dysfunction-associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study.
    van Kleef LA; Ayada I; Alferink LJM; Pan Q; de Knegt RJ
    Hepatology; 2022 Feb; 75(2):419-429. PubMed ID: 34453359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAFLD Predicts the Risk of Cardiovascular Disease Better than NAFLD in Asymptomatic Subjects with Health Check-Ups.
    Kim H; Lee CJ; Ahn SH; Lee KS; Lee BK; Baik SJ; Kim SU; Lee JI
    Dig Dis Sci; 2022 Oct; 67(10):4919-4928. PubMed ID: 35579799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease?
    Younossi ZM; Paik JM; Al Shabeeb R; Golabi P; Younossi I; Henry L
    Hepatology; 2022 Nov; 76(5):1423-1437. PubMed ID: 35363908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Open Issues in the Transition from NAFLD to MAFLD: The Experience of the Plinio Study.
    Baratta F; Ferro D; Pastori D; Colantoni A; Cocomello N; Coronati M; Angelico F; Del Ben M
    Int J Environ Res Public Health; 2021 Aug; 18(17):. PubMed ID: 34501590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of nonalcoholic fatty liver disease (NAFLD) related steatosis indices in metabolic associated fatty liver disease (MAFLD) and comparison of the diagnostic accuracy between NAFLD and MAFLD.
    Chen J; Mao X; Deng M; Luo G
    Eur J Gastroenterol Hepatol; 2023 Apr; 35(4):394-401. PubMed ID: 36695773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact renaming non-alcoholic fatty liver disease to metabolic associated fatty liver disease in prevalence, characteristics and risk factors.
    Huang XJ; Yin M; Zhou BQ; Tan XY; Xia YQ; Qin CX
    World J Hepatol; 2023 Aug; 15(8):985-1000. PubMed ID: 37701916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?
    Kang SH; Cho Y; Jeong SW; Kim SU; Lee JW;
    Clin Mol Hepatol; 2021 Apr; 27(2):257-269. PubMed ID: 33751877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement.
    Eslam M; Alkhouri N; Vajro P; Baumann U; Weiss R; Socha P; Marcus C; Lee WS; Kelly D; Porta G; El-Guindi MA; Alisi A; Mann JP; Mouane N; Baur LA; Dhawan A; George J
    Lancet Gastroenterol Hepatol; 2021 Oct; 6(10):864-873. PubMed ID: 34364544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-Rather a Bystander Than a Driver of Mortality.
    Semmler G; Wernly S; Bachmayer S; Leitner I; Wernly B; Egger M; Schwenoha L; Datz L; Balcar L; Semmler M; Stickel F; Niederseer D; Aigner E; Datz C
    J Clin Endocrinol Metab; 2021 Aug; 106(9):2670-2677. PubMed ID: 33982065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States.
    Kim D; Konyn P; Sandhu KK; Dennis BB; Cheung AC; Ahmed A
    J Hepatol; 2021 Dec; 75(6):1284-1291. PubMed ID: 34380057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
    Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
    Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
    Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
    Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.